SELLAS Life Sciences Group, Inc. Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
SELLAS Life Sciences Group, Inc. (SLS) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of -$4.44 million for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-13.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2020-03-13
- SELLAS Life Sciences Group, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2018-12-31 was $0.00.
- SELLAS Life Sciences Group, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2018-09-30 was $0.00.
- SELLAS Life Sciences Group, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2018-06-30 was -$2.47M.
- SELLAS Life Sciences Group, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2018-03-31 was -$1.97M.
- SELLAS Life Sciences Group, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2018 was -$4.44M.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 3 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 6 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 9 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $0.00 derived: sum of 2 quarters · filed 2020-03-13 | -$2.47M derived: sum of 3 quarters · filed 2020-03-13 | -$4.44M 10-K · filed 2020-03-13 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | -$2.47M derived: sum of 2 quarters · filed 2019-11-14 | -$4.44M 10-Q · filed 2019-11-14 | |
| 2018-06-30 | -$2.47M 10-Q · filed 2019-08-14 | -$4.44M 10-Q · filed 2019-08-14 | ||
| 2018-03-31 | -$1.97M 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |